October 2, 2023
European Patent Office grants patent for Futura Medical’s product
Futura Medical, a UK pharmaceutical company developing innovative sexual health products, has been granted allowance of its EU patent which…
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
September 29, 2023
OptiBiotix Health increase gross profit in first six months 2023
OptiBiotix Health, a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, finished first half of trading with sales of £351k, compared to the year 2022 sales of the same period, of £119k, which is a 195% increase over, the company said in its unaudited results for the six months ended 30 June 2023.
September 29, 2023
Hemogenyx Pharmaceuticals encouraged by the FDA’s response to plans to resolve a setback
Hemogenyx Pharmaceuticals, the Standard Listed biopharmaceutical group developing therapies designed to transform blood disease treatment, committed to progressing HEMO CAR-T to clinical trials as the its next step.
September 29, 2023
4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
The US Food and Drug Administration (FDA) has granted Germany based 4SC’s application for Orphan Drug Designation for resminostat (Kinselby) for cutaneous T cell lymphoma (CTCL), the company said in a press release on Wednesday.
September 29, 2023
Sartorius Forms Partnership with SPARTA Biodiscovery on Novel Nanoparticle Analysis Platform
The life science group Sartorius and a UK-based startup SPARTA Biodiscovery have agreed to partner on SPARTA’s analysis platform, which helps speed up the development, manufacture, and quality control of nanoparticles for biopharmaceutical drugs.
September 29, 2023
FDA puts Dupixent in priority review for treatment of eosinophilic esophagitis in children younger than 12
Regeneron Pharmaceuticals and Sanofi have received U.S. Food and Drug Administration (FDA) acceptance for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat children aged 1 to 11 years with eosinophilic esophagitis (EoE).
September 25, 2023
Lundbeckfonden BioCapital and +ND Capital join forces
The two investors are already partners on the Danish biotech scene, and this new investment underlines Lundbeckfonden BioCapital’s longstanding commitment to Danish science and the local biotech ecosystem.
September 25, 2023
GSK gets Japan’s approval for RSV vaccine for older adults
Japan’s Ministry of Health, Labour and Welfare has approved GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults.
September 25, 2023
MC2 Therapeutics gets option rights for oral drug candidate for Hidradenitis Suppurativa
MC2 Therapeutics has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human…
September 22, 2023
United Lincolnshire Hospitals NHS Trust, Boehringer Ingelheim, launch new cardio-diabetic outpatient service
As part of a collaborative working agreement between United Lincolnshire Hospitals NHS Trust and pharmaceutical company Boehringer Ingelheim, a new cardio-diabetic outpatient service has been launched to help reduce recurring heart attacks in people with diabetes.